Golimumab (CNTO-148) 是一种有效的人 IgG1TNFα拮抗剂单克隆抗体。Golimumab 具有抗炎活性，并抑制 IL-6 和 IL-1β 的产生。Golimumab 通过靶向和中和 TNF 来防止炎症发生和软骨或骨骼的破坏。Golimumab 具有抗癌活性并诱导细胞凋亡 (apoptosis)。Golimumab 可用于类风湿关节炎、克罗恩病和癌症研究。
| 生物活性 | Golimumab (CNTO-148) is a potent humanIgG1TNFαantagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibitsIL-6and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cellapoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease andcancerresearch[1][2][3]. |
| IC50& Target[1] | |
体外研究
(In Vitro) | Golimumab (CNTO-148) (0.1-10 μg /mL; 24-72 hours; transmembrane TNFα–transfected Jurkat cells) induces reductions in the viability of transmembrane TNFα–expressing cells[1].
Golimumab (CNTO-148) (10 μg /mL; 48 hours; transmembrane TNFα–transfected Jurkat cells) induces apoptosis, increase the levels of active caspase-3 and induces apoptotic DNA fragmentation[1].
Cell Viability Assay[1] | Cell Line: | Transmembrane TNFα–transfected Jurkat cells | | Concentration: | 0.1, 1 and 10 μg/mL | | Incubation Time: | 24, 48 and 72 hours | | Result: | Reduced cell viability in a dose- and time-dependent manner. |
Apoptosis Analysis[1] | Cell Line: | Transmembrane TNFα–transfected Jurkat cells | | Concentration: | 10 μg /mL | | Incubation Time: | 48 hours | | Result: | Had the percentage of apoptotic cells for 30.29%. |
Western Blot Analysis[1] | Cell Line: | Transmembrane TNFα–transfected Jurkat cells | | Concentration: | 10 μg /mL | | Incubation Time: | 48 hours | | Result: | Increased the levels of active caspase-3 and induces apoptotic DNA fragmentation. |
|
体内研究
(In Vivo) | Golimumab (CNTO-148) (24 mg/kg; i.h.; daily, for 7 days; swiss-albino healthy male mice) inhibits oxidative stress, apoptotic cell death inflammatory response, thus improving renal function. Golimumab reduces all markers of kidney injury and attenuates cell death[2].
Golimumab (CNTO-148) (1-10 mg/kg; i.p.;daily; for 4 weeks; Tg197 transgenic mouse model) relieves TNFα-induced arthritis in a mouse model of human[3].
| Animal Model: | Swiss-albino healthy male mice[2] | | Dosage: | 24 mg/kg | | Administration: | Subcutaneous injection; daily, for 7 days | | Result: | Reduced serum parameters like BUN, NGAL creatinine, cystatin C, and urinary parameters like KIM-1, NAG, albumin clusterin. |
| Animal Model: | Swiss-albino healthy male mice[2] | | Dosage: | 24 mg/kg | | Administration: | Subcutaneous injection; daily, for 7 days | | Result: | Inhibited oxidative stress, reduces MDA concentrations and increases the GSH and catalase levels. |
| Animal Model: | Swiss-albino healthy male mice[2] | | Dosage: | 24 mg/kg | | Administration: | Subcutaneous injection; daily, for 7 days | | Result: | Inhibitd cisplatin-induced inflammation, decreased TNF-α, including IL-6, IL-1β, MCP-1, ICAM-1, and TGF-β1 levels and increases IL-10 concentrations, reduced caspase 3 in cisplatin injected mice kidneys. |
| Animal Model: | Tg197 transgenic mouse model[3] | | Dosage: | 1 and 10 mg/kg | | Administration: | Intraperitoneal injection;for 4 weeks | | Result: | Reduced the arthritic index. |
|
| Clinical Trial | |
| 性状 | |
| CAS 号 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com